ClinicalTrials.gg
CompletedNCT00109733Updated Aug 7, 2013Results posted

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

A Phase 3 interventional study of recombinant human growth hormone and recombinant human growth hormone in Childhood-onset Growth Hormone Deficiency and Pituitary Dwarfism, sponsored by EMD Serono. Completed at 9 sites in United States. Open to participants aged 13 Years to 25 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
13 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
40th of 60
31 · median 66
Started
2005
with 4 others
Phase 3
23 of 60
2 open now
Registered
3rd of 60
by date
Lead sponsor
3 of 60
EMD Serono

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 40th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 3rd registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 13 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.

Read the detailed description

This is a phase IIIb, prospective, multicenter, randomised, open label study to determine the safety and efficacy of two different dose regimens of r-hGH with a dose escalation scheme. Screening assessments must be completed 30 days prior to SD1 (Study Day 1). Eligible subjects ages 13 to 25 years will be randomised in equal allocation in a 1:1 ratio to one of two treatment groups (30 subjects/group). Daily subcutaneous injections will be self-administered or received from a designated individual using cool.click™, the needle-free growth hormone (GH) delivery device. The study consists of three periods: screening (up to 30 days prior to Study Day 1), active treatment (up to 24 weeks), and follow-up (4 week safety evaluation after the last dose of study medication).

Each subject will be required to complete a daily treatment diary to assess dosing compliance, adverse events, and concomitant medications. Each subject will receive one treatment diary at SD1, weeks 8, 12, and 24. Subjects will be required to record daily diary entries that will capture dosing compliance, adverse events, and concomitant medications. Depending upon treatment allocation and subject tolerability, dose titration will be increased as follows:

  • Group A: 0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from day 31 to week 24.
  • Group B: 0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on day 15 to 0.02 mg/kg/day and day 29 to 0.03 mg/kg/day.

Scheduled study visits include screening, baseline, and weeks 8, 12, and 24. Dosage adjustments will be based on subject tolerability and telephone assessments from study drug initiation through week 6. Trunk fat will be measured at SD1, weeks 12 and 24 (or early termination visit). Routine clinical laboratory assessments (hematology, blood chemistries, and urinalysis) will be performed pre-treatment (-30 to -1 SD1) and post-treatment on week 24 (or early termination visit). Special laboratory assessments include the central analysis of lipid panel, fasting insulin, fasting glucose, insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), free thyroxine (T4) , total T4, C-reactive protein (CRP). Physical exams will be performed at screening, weeks 12 and 24. Safety evaluations will occur during scheduled study visits, through telephone assessments, and by the review of adverse events and concomitant events on the subject treatment diary.

03

Conditions studied

  • Childhood-onset Growth Hormone Deficiency
  • Pituitary Dwarfism

Browse trials for

Keywords

  • Childhood-onset growth hormone deficiency (COGHD)
  • Saizen®
04

Who can participate

Ages eligible
13 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The day of entry or Study Day 1 is defined as the first day of study treatment. To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria within 30 days prior to Study Day 1.

  • Male or female from 13 to 25 years of age, inclusive
  • Diagnosis of childhood onset growth hormone deficiency (GHD) and prior completed growth hormone (GH) treatment as evidenced by bone age greater than 14 years for girls and 16 years for boys or no height increase > 0.5 cm in the 6 months prior to Screen.
  • Have documented GH deficiency (acquired or idiopathic), established by a standard provocative test, such as insulin (\<5 ng/mL) or growth hormone releasing hormone plus arginine (\<9 ng/mL) at least 30 days after GH has been discontinued. If a subject is hypopituitary with two or more pituitary disorders and has a low IGF-1, the stimulation test does not need to be performed to confirm GHD.
  • If hypopituitary, must have been on adequate replacement therapy (if required) of glucocorticosteroids, thyroid and sex hormones (hormone levels on replacement being in normal/mildly elevated range) for at least 6 months prior to Screen.
  • Be willing and able to comply with the protocol for the duration of the study.
  • Have given written before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
  • Female subjects of must use a hormonal , intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Confirmation that a female patient is not pregnant must be established by a negative human chorionic gonadotrophin (hCG) pregnancy test (urine or serum) within 7 days of study enrolment (SD1).

Exclusion criteria

Exclusion Criteria:

To be eligible for inclusion in this study the subjects must not meet any of the following criteria:

  • Known allergy or to growth hormone or diluent.
  • Previous treatment with GH within six months prior to Screen.
  • Severe illness during the previous six months.
  • Active (except non-melanomatous skin malignancies).
  • Diabetes mellitus (type I or II).
  • Seropositivity for (HIV), surface antigen (HbsAg) and/or Virus (HCV) serology.
  • Pregnancy or lactation.
  • History of drug and/or alcohol abuse or use of drugs for non-therapeutic purposes.
  • Any medical condition that, in the opinion of the Investigator, would jeopardize the patient's safety following exposure to study drug.
  • abnormal hematology, chemistry or urinalysis results at screening in the judgment of the Investigator.
  • Have taken another drug or had any experimental procedure in the six months preceding study entry.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Standard dose group

    0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.

    Biological: recombinant human growth hormone

  • Experimental
    High dose group

    0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.

    Biological: recombinant human growth hormone

Interventions

  • BiologicalHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.

    Also known as: Saizen, r-hGH, cool click

  • BiologicalHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.

    Also known as: Saizen, r-hGH, cool click

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 24 in Trunk Fat

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline to Week 24 in Lean Body Mass

    Time frame: Baseline to Week 24

  2. Percent Change From Baseline to Week 24 in Total Body Fat

    Time frame: Baseline to Week 24

  3. Percent Change From Baseline to Week 24 in Limb Fat

    Time frame: Baseline to Week 24

  4. Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio

    Time frame: Baseline to Week 24

07

Results

Posted Jun 22, 2010

Participant flow

Study Initiation Date: 06 Jan 2005 (date of first subject, first dose) Study Completion Date 11 Jun 2006 (date of last subject, last visit) 19 study centres in the United States received IRB approval to participate in this study; 13 of the centres enrolled at least one subject into the study.

Participant flow — Overall Study
MilestoneStandard Dose GroupHigh Dose Group
Started1516
Completed1312
Not completed24
Withdrew: Protocol violation01
Withdrew: Stopped taking study drug11
Withdrew: Non-compliant01
Withdrew: Could not commit time for study11

Outcome measures

PrimaryPercent Change From Baseline to Week 24 in Trunk Fat
Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Trunk Fat
percent changeStandard Dose GroupHigh Dose Group
Percent Change From Baseline to Week 24 in Trunk Fat-6.27 ± 12.72-8.36 ± 17.69
Statistical analysis
  • Standard Dose Group · ANOVA · p = 0.177
  • High Dose Group · ANOVA · p = 0.004
SecondaryPercent Change From Baseline to Week 24 in Lean Body Mass
Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Lean Body Mass
percent changeStandard Dose GroupHigh Dose Group
Percent Change From Baseline to Week 24 in Lean Body Mass3.85 ± 4.057.10 ± 5.02
Statistical analysis
  • Standard Dose Group · ANOVA · p = 0.004
  • High Dose Group · ANOVA · p = <0.001
SecondaryPercent Change From Baseline to Week 24 in Total Body Fat
Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Total Body Fat
percent changeStandard Dose GroupHigh Dose Group
Percent Change From Baseline to Week 24 in Total Body Fat-4.62 ± 9.96-9.69 ± 10.54
Statistical analysis
  • Standard Dose Group · ANOVA · p = 0.653
  • High Dose Group · ANOVA · p = 0.002
SecondaryPercent Change From Baseline to Week 24 in Limb Fat
Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Limb Fat
percent changeStandard Dose GroupHigh Dose Group
Percent Change From Baseline to Week 24 in Limb Fat-3.77 ± 8.85-11.09 ± 8.97
Statistical analysis
  • Standard Dose Group · ANOVA · p = 0.755
  • High Dose Group · ANOVA · p = <0.001
SecondaryPercent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio
Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio
percent changeStandard Dose GroupHigh Dose Group
Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio-2.86 ± 6.772.92 ± 16.16
Statistical analysis
  • Standard Dose Group · ANOVA · p = 0.041
  • High Dose Group · ANOVA · p = 0.044

Adverse events

Collected over Baseline to Week 28(+/-5 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Dose Group—0/15 (0%)13/15 (86.7%)
High Dose Group—1/16 (6.3%)14/16 (87.5%)
Most frequent serious events
Most frequent serious events
EventStandard Dose GroupHigh Dose Group
AsthmaRespiratory, thoracic and mediastinal disorders0/151/16
Most frequent other events
Showing 10 of 50
Most frequent other events
EventStandard Dose GroupHigh Dose Group
HeadacheNervous system disorders6/156/16
Upper respiratory tract infectionInfections and infestations4/153/16
ArthralgiaMusculoskeletal and connective tissue disorders3/150/16
NasopharyngitisInfections and infestations1/153/16
SinusitisInfections and infestations0/153/16
DysmenorrhoeaReproductive system and breast disorders2/151/16
Injection site bruisingGeneral disorders2/151/16
Back painMusculoskeletal and connective tissue disorders0/152/16
DiarrhoeaGastrointestinal disorders0/152/16
Abdominal pain upperGastrointestinal disorders1/151/16

Baseline characteristics

Age Continuous
Age Continuous(years)Standard Dose GroupHigh Dose GroupTotal
Mean17.4 ± 1.818.1 ± 1.917.8 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Standard Dose GroupHigh Dose GroupTotal
Female5611
Male101020
Region of Enrollment
Region of Enrollment(participants)Standard Dose GroupHigh Dose GroupTotal
United States151631
Lean body mass
Lean body mass(kg)Standard Dose GroupHigh Dose GroupTotal
Mean44.03 ± 11.0944.38 ± 12.9844.21 ± 11.90
Limb fat
Limb fat(kg)Standard Dose GroupHigh Dose GroupTotal
Mean11.47 ± 5.4912.92 ± 9.2812.22 ± 7.59
Total body fat
Total body fat(kg)Standard Dose GroupHigh Dose GroupTotal
Mean24.02 ± 10.8125.11 ± 18.2924.58 ± 14.90
Trunk fat
Trunk fat(kg)Standard Dose GroupHigh Dose GroupTotal
Mean11.73 ± 5.5811.40 ± 9.0911.56 ± 7.47
Trunk to limb fat ratio
Trunk to limb fat ratio(ratio)Standard Dose GroupHigh Dose GroupTotal
Mean1.05 ± 0.290.87 ± 0.170.96 ± 0.25
08

Study locations

9 sites
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Nemours Children's Clinic
    Jacksonville, Florida 32226, United States
  • Nemours Children's Clinic
    Orlando, Florida 32806, United States
  • Pediatric Endocrinology Children's Clinic
    Tallahassee, Florida 32308, United States
  • Pediatric Endocrine Associates
    Atlanta, Georgia 30342, United States
  • Women's and Children's Hospital of Buffalo
    Buffalo, New York 14222, United States
  • Columbia University
    New York, New York 10032, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jun 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2005
First posted
May 3, 2005
Start
Jan 2005
Primary completionActual
Jun 2006
CompletionActual
Jul 2006
Results first posted
Jun 22, 2010
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00109733
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
May 3, 2005
Start date
Jan 2005
Primary completion
Jun 2006
Completion
Jul 2006
Results posted
Jun 22, 2010
Last update
Aug 7, 2013

Study contacts

Sanja Dragnic, MD
study director · EMD Serono
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion